Cancer Discovery

Top Research Topics at Cancer Discovery?

The discussions in Cancer Discovery mainly cover the fields of Cancer research, Cancer, Immunology, Internal medicine and Bioinformatics. Specifically, studies on Tumor microenvironment are prevalent in the Cancer research works discussed. While Cancer Discovery focused on Cancer, it was also able to explore topics like Lung cancer and Clinical trial.

The studies on Internal medicine discussed can also contribute to research in the domains of Endocrinology and Oncology. The majority of Immune system studies presented zero in on Immunotherapy. In particular, the Genetics works presented emphasize discussions on Gene.

Research on Mutation addressed in Cancer Discovery frequently intersections with the field of Mutant.

• Cancer research (58.54%)
• Cancer (39.25%)
• Immunology (14.37%)

What are the most cited papers published in the journal?

• The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data (8041 citations)
• The emergence of lncRNAs in cancer biology. (1276 citations)
• Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy (1201 citations)

Research areas of the most cited articles at Cancer Discovery:

The journal publications explore disciplines such as Cancer research, Cancer, Immunology, Mutation and Bioinformatics. Melanoma is a major topic of Cancer research research in the most cited papers. In addition to Cancer research, the most cited publications aim to explore topics under Lung cancer, Oncology and Pharmacology.

What topics the last edition of the journal is best known for?

• Gene
• Cancer
• Internal medicine

The previous edition focused in particular on these issues:

The journal focuses on Cancer research, Cancer, Immune system, Immunotherapy and Internal medicine. Myeloid leukemia is the primary subject of Cancer research works presented in the journal. Cancer Discovery addresses concerns in the field of Cancer by exploring it in line with topics in CRISPR which intersect with Computational biology subjects.

Most of the works presented in it deals with Immune system but it intersects with the subject of Cytotoxic T cell. It connects research in Immunotherapy with the related topic of Blockade. Research in Oncology and the interrelating topic of Clinical trial, Disease and Chemotherapy were among the subjects of interest in the Internal medicine studies discussed in Cancer Discovery.

The most cited articles from the last journal are:

• Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. (58 citations)
• BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition (47 citations)
• The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells (35 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Cancer Discovery (based on the number of publications) are:

• Antoni Ribas (26 papers) published 8 papers at the last edition, 4 more than at the previous edition,
• Kwok-Kin Wong (23 papers) published 4 papers at the last edition, 3 more than at the previous edition,
• Levi A. Garraway (22 papers) absent at the last edition,
• Ari Melnick (20 papers) published 3 papers at the last edition, 1 more than at the previous edition,
• Neal Rosen (20 papers) published 1 paper at the last edition, 1 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Cancer Discovery (based on the number of publications) are:

• Harvard University (328 papers) published 58 papers at the last edition, 24 more than at the previous edition,
• Memorial Sloan Kettering Cancer Center (192 papers) published 33 papers at the last edition, 6 more than at the previous edition,
• University of Texas MD Anderson Cancer Center (144 papers) published 31 papers at the last edition, 13 more than at the previous edition,
• Cornell University (98 papers) published 22 papers at the last edition, 8 more than at the previous edition,
• University of California, San Francisco (91 papers) published 9 papers at the last edition, 1 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 3.86% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 48.18% were posted by at least one author from the top 10 institutions publishing in the journal. Another 12.04% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 21.17% of all publications and 18.61% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Potential Research Allies

While Cancer Discovery has consistently delivered impactful and groundbreaking research, collaboration with other research entities could also help. By partnering with other institutions that offer advanced and specialized courses related to cancer research, both the scope and the quality of the studies could be significantly enhanced. For example, institutions that feature top-notch lpn programs washington could provide valuable insights and collaborative opportunities, especially in the area of clinical trials and Oncology.

These collaborations aren't just limited to academic institutions; research centers and hospitals can also be possible allies in the pursuit of understanding cancer better. This is especially crucial for Cancer Discovery which largely focuses on Cancer, Immunotherapy, and Internal medicine. Potentially, research done in collaboration with these institutions can help uncover new treatment methods, thereby pushing the boundaries of what is currently possible in cancer treatment.

Through strategic partnerships and collaborative efforts, Cancer Discovery can continue to build on its reputation as a forward-thinking and dynamic player in the field of cancer research. With the right alliances, the journal can unlock new avenues of research, helping scientists and researchers worldwide in their mission to find a cure for cancer.